# Admilparant PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/admilparant

> The next catalyst for admilparant, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its topline data readout, Nov 2029 to Feb 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | admilparant |
| Codes | BMS-986278 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Pulmonary Fibrosis](https://sec-api.dev/indications/pulmonary-fibrosis), [Idiopathic Pulmonary Fibrosis](https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Idiopathic Pulmonary Fibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06003426 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06003426

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Idiopathic Pulmonary Fibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06003426 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06003426

### Nov 2029 to Feb 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Fibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07441408 (Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-11-22 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07441408

### November 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Fibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07441408 (Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-11-22 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07441408

## Same indication

- [ABBV-142](https://sec-api.dev/pdufa/abbv-142) (ABBV)
- [GSK3915393](https://sec-api.dev/pdufa/gsk3915393) (GSK)
- [Vasculan® (ifetroban)](https://sec-api.dev/pdufa/ifetroban) (CPIX)
- [Inhaled treprostinil](https://sec-api.dev/pdufa/inhaled-treprostinil) (UTHR)
- [Nal er](https://sec-api.dev/pdufa/nal-er) (TRVI)
- [Nintedanib dry powder inhalation](https://sec-api.dev/pdufa/nintedanib-dry-powder-inhalation) (MNKD)
- [Pipe-791 dose a](https://sec-api.dev/pdufa/pipe-791) (CTNM)
- [Pirfenidone solution](https://sec-api.dev/pdufa/pirfenidone-solution) (AVLN)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/admilparant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Admilparant PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/admilparant

```bibtex
@misc{secapidev_pdufa_admilparant_20261116,
  title        = {Admilparant PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/admilparant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_admilparant_20261116","title":"Admilparant PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/admilparant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
